Transcode Therapeutics, Inc. (RNAZ)
CIK 1829635 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 16.9M shares as of Aug 10, 2026 (10-Q). Share count fell from 23.3M to 833,683 between May 12, 2025 and Aug 8, 2025, a pattern consistent with a reverse split (roughly 1-for-28); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| March2025 Warrants | 366,080 | $24.08 | 5y | — |
| Series C Warrants | 144,682 | $348.35 | 5y | FV $330,526 |
| March2025 Placement Agents Warrants | 18,290 | $29.96 | 5y | — |
| January2024 Warrants At Exercise Price1127.28 | 6,749 | $1127.28 | 3.5y | — |
| January2024 Warrants At Exercise Price438.90 | 5,423 | $438.9 | — | — |
| July Placement Agent Warrants | 548 | $346.5 | — | — |
| July2024 Placement Agents Warrants | 548 | $346.5 | — | — |
| January Placement Agent Warrants | 388 | $1409.1 | 3.5y | — |
| September2023 Underwriter Warrants | 33 | $23562 | 5y | — |
| Ipo Underwriter Warrants | 20 | $3696000 | 5y | — |
| December2023 Placement Agent Warrants | 18 | $10648.18 | 5y | — |
| October2023 Underwriter Overallotment Warrants | 16 | $23562 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 14, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 20 underlying shares, as reported Dec 31, 2025 (10-K).
Reported exercise price: $3696000 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 16.9M = 16.9M O/S + 20 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Convertible Notes Payable Tranche One | $1.0M | — | $10.71 | — | ~93,371 sh |
If every note above converted at its tagged price: ~93,371 new shares on 16.9M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 14, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 16.9M | Aug 10, 2026 |
| + March2025 Warrants (if exercised) | 366,080 | Jun 30, 2026 |
| + Series C Warrants (if exercised) | 144,682 | Jun 30, 2026 |
| + March2025 Placement Agents Warrants (if exercised) | 18,290 | Jun 30, 2026 |
| + January2024 Warrants At Exercise Price1127.28 (if exercised) | 6,749 | Jun 30, 2026 |
| + January2024 Warrants At Exercise Price438.90 (if exercised) | 5,423 | Jun 30, 2026 |
| + July Placement Agent Warrants (if exercised) | 548 | Jul 22, 2024 |
| + July2024 Placement Agents Warrants (if exercised) | 548 | Jun 30, 2026 |
| + January Placement Agent Warrants (if exercised) | 388 | Jun 30, 2026 |
| + September2023 Underwriter Warrants (if exercised) | 33 | Jun 30, 2026 |
| + Ipo Underwriter Warrants (if exercised) | 20 | Jun 30, 2026 |
| + December2023 Placement Agent Warrants (if exercised) | 18 | Jun 30, 2026 |
| + October2023 Underwriter Overallotment Warrants (if exercised) | 16 | Jun 30, 2026 |
| + Convertible Notes Payable Tranche One (if fully converted) | 93,371 | Apr 16, 2026 |
| Fully diluted estimate | 17.6M | +3.8% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $297.4Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 3 executed · 3 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full RNAZ workspace